CorMedix Announces Positive Phase III Results for REZZAYO, Meeting Primary Endpoint for Fungal Prophylaxis
CRMD sits 22% above its 52-week low of $6.125.
Summary
CorMedix announced positive Phase III clinical trial results for REZZAYO, meeting its primary endpoint for prophylaxis of invasive fungal infections and opening a substantial new market opportunity.
Key Events · Product Development and Regulatory · CRMD
-
Positive Phase III Clinical Trial Results
CorMedix announced positive topline results from the global ReSPECT Phase III study for REZZAYO® (rezafungin for injection).
-
Primary Endpoint Met
The study met its primary endpoint, demonstrating non-inferiority versus standard antimicrobial regimen in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for SAR).
-
Favorable Safety and Interaction Profile
REZZAYO was well tolerated with a safety profile comparable to standard regimens, showing favorable benefits for toxicity-related discontinuations and drug-drug interactions.
-
Significant Market Opportunity
The company estimates the potential US market opportunity for REZZAYO in prophylaxis exceeds $2 billion, supported by orphan drug exclusivity through 2035 and patent coverage through 2038.
Analysis · CRMD · Life Sciences
CorMedix has reported highly positive topline results from its Phase III ReSPECT trial for REZZAYO, demonstrating non-inferiority in fungal-free survival for prophylaxis of invasive fungal infections. This successful outcome significantly de-risks the drug's potential for an expanded indication, opening up an estimated US market opportunity exceeding $2 billion. The favorable safety profile and reduced drug-drug interactions further enhance REZZAYO's competitive positioning. This clinical milestone is crucial for CorMedix, building on its recent financial turnaround and providing a strong growth driver for future revenue, with an sNDA submission targeted for the second half of 2026.
At the time of this filing, CRMD was trading at $7.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $581.9M. The 52-week trading range was $6.13 to $17.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.